Search Results - "BORTHAKUR, GAUTAM"

Stressing the stem cell in acute myeloid leukemia by Borthakur, Gautam

Get full text

Core binding factor acute myelogenous leukemia-2021 treatment algorithm by Borthakur, Gautam, Kantarjian, Hagop

“…Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered…”
Get full text

Acute myeloid leukemia: current progress and future directions by Kantarjian, Hagop, Kadia, Tapan, DiNardo, Courtney, Daver, Naval, Borthakur, Gautam, Jabbour, Elias, Garcia-Manero, Guillermo, Konopleva, Marina, Ravandi, Farhad

“…Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for…”
Get full text

De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017 by Sasaki, Koji, Ravandi, Farhad, Kadia, Tapan M., DiNardo, Courtney D., Short, Nicholas J., Borthakur, Gautam, Jabbour, Elias, Kantarjian, Hagop M.

“…Background Several important treatment and supportive care strategies have been implemented over the past 4 decades in the management of acute myeloid leukemia…”
Get full text

Ibrutinib and Venetoclax for First-Line Treatment of CLL by Jain, Nitin, Keating, Michael, Thompson, Philip, Ferrajoli, Alessandra, Burger, Jan, Borthakur, Gautam, Takahashi, Koichi, Estrov, Zeev, Fowler, Nathan, Kadia, Tapan, Konopleva, Marina, Alvarado, Yesid, Yilmaz, Musa, DiNardo, Courtney, Bose, Prithviraj, Ohanian, Maro, Pemmaraju, Naveen, Jabbour, Elias, Sasaki, Koji, Kanagal-Shamanna, Rashmi, Patel, Keyur, Jorgensen, Jeffrey, Garg, Naveen, Wang, Xuemei, Sondermann, Katrina, Cruz, Nichole, Wei, Chongjuan, Ayala, Ana, Plunkett, William, Kantarjian, Hagop, Gandhi, Varsha, Wierda, William

“…The BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active in chronic lymphocytic leukemia, and each has distinct adverse effects. The…”
Get full text

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials by Atkins, Johnique T., George, Goldy C., Hess, Kenneth, Marcelo-Lewis, Kathrina L., Yuan, Ying, Borthakur, Gautam, Khozin, Sean, LoRusso, Patricia, Hong, David S.

“…Background Our objective was to determine the correlation between preclinical toxicity found in animal models (mouse, rat, dog and monkey) and clinical…”
Get full text

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status by CORTES, Jorge E, KANTARJIAN, Hagop, LEVIS, Mark, FORAN, James M, GHIRDALADZE, Darejan, ZODELAVA, Mamia, BORTHAKUR, Gautam, GAMMON, Guy, TRONE, Denise, ARMSTRONG, Robert C, JAMES, Joyce

“…FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) are associated with early relapse and poor…”
Get full text

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia by Naqvi, Kiran, Jabbour, Elias, Skinner, Jeffrey, Anderson, Kristin, Dellasala, Sara, Yilmaz, Musa, Ferrajoli, Alessandra, Bose, Prithviraj, Thompson, Philip, Alvarado, Yesid, Jain, Nitin, Takahashi, Koichi, Burger, Jan, Estrov, Zeev, Borthakur, Gautam, Pemmaraju, Naveen, Paul, Shilpa, Cortes, Jorge, Kantarjian, Hagop M.

“…Background Dasatinib, a potent Bcr‐Abl tyrosine kinase inhibitor, is approved for the treatment of chronic‐phase chronic myeloid leukemia (CML‐CP) in the…”
Get full text

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality by Ishizawa, Jo, Zarabi, Sarah F., Davis, R. Eric, Halgas, Ondrej, Nii, Takenobu, Jitkova, Yulia, Zhao, Ran, St-Germain, Jonathan, Heese, Lauren E., Egan, Grace, Ruvolo, Vivian R., Barghout, Samir H., Nishida, Yuki, Hurren, Rose, Ma, Wencai, Gronda, Marcela, Link, Todd, Wong, Keith, Mabanglo, Mark, Kojima, Kensuke, Borthakur, Gautam, MacLean, Neil, Ma, Man Chun John, Leber, Andrew B., Minden, Mark D., Houry, Walid, Kantarjian, Hagop, Stogniew, Martin, Raught, Brian, Pai, Emil F., Schimmer, Aaron D., Andreeff, Michael

“…The mitochondrial caseinolytic protease P (ClpP) plays a central role in mitochondrial protein quality control by degrading misfolded proteins. Using genetic…”
Get full text

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes by Kadia, Tapan M., Jain, Preetesh, Ravandi, Farhad, Garcia‐Manero, Guillermo, Andreef, Michael, Takahashi, Koichi, Borthakur, Gautam, Jabbour, Elias, Konopleva, Marina, Daver, Naval G., Dinardo, Courtney, Pierce, Sherry, Kanagal‐Shamanna, Rashmi, Patel, Keyur, Estrov, Zeev, Cortes, Jorge, Kantarjian, Hagop M.

“…BACKGROUND Mutations in the tumor protein 53 (TP53) gene predict a poor prognosis in patients with acute myeloid leukemia (AML). METHODS Peripheral blood or…”
Get full text

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms by Zhang, Haijiao, Savage, Samantha, Schultz, Anna Reister, Bottomly, Daniel, White, Libbey, Segerdell, Erik, Wilmot, Beth, McWeeney, Shannon K., Eide, Christopher A., Nechiporuk, Tamilla, Carlos, Amy, Henson, Rachel, Lin, Chenwei, Searles, Robert, Ho, Hoang, Lam, Yee Ling, Sweat, Richard, Follit, Courtney, Jain, Vinay, Lind, Evan, Borthakur, Gautam, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop M., Cortes, Jorge, Collins, Robert, Buelow, Daelynn R., Baker, Sharyn D., Druker, Brian J., Tyner, Jeffrey W.

“…FLT3 mutations are prevalent in AML patients and confer poor prognosis. Crenolanib, a potent type I pan-FLT3 inhibitor, is effective against both internal…”
Get full text

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN by Jabbour, Elias, Short, Nicholas J., Montalban-Bravo, Guillermo, Huang, Xuelin, Bueso-Ramos, Carlos, Qiao, Wei, Yang, Hui, Zhao, Chong, Kadia, Tapan, Borthakur, Gautam, Pemmaraju, Naveen, Sasaki, Koji, Estrov, Zeev, Cortes, Jorge, Ravandi, Farhad, Alvarado, Yesid, Komrokji, Rami, Sekeres, Mikkael A., Steensma, David P., DeZern, Amy, Roboz, Gail, Kantarjian, Hagop, Garcia-Manero, Guillermo

“…Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We…”
Get full text

Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment by WALTER, Roland B, OTHUS, Megan, BORTHAKUR, Gautam, RAVANDI, Farhad, CORTES, Jorge E, PIERCE, Sherry A, APPELBAUM, Frederick R, KANTARJIAN, Hagop A, ESTEY, Elihu H

“…Outcome in acute myeloid leukemia (AML) worsens with age, at least in part because of higher treatment-related mortality (TRM) in older patients. Eligibility…”
Get full text

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia by Daver, Naval, Thomas, Deborah, Ravandi, Farhad, Cortes, Jorge, Garris, Rebecca, Jabbour, Elias, Garcia-Manero, Guillermo, Borthakur, Gautam, Kadia, Tapan, Rytting, Michael, Konopleva, Marina, Kantarjian, Hagop, O'Brien, Susan

“…We have previously reported on the efficacy and tolerability of hyper-CVAD regimen (cyclophosphamide, vincristine, Adriamycin, and dexamethasone) and imatinib…”
Get full text

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy by Venugopal, Sangeetha, Takahashi, Koichi, Daver, Naval, Maiti, Abhishek, Borthakur, Gautam, Loghavi, Sanam, Short, Nicholas. J., Ohanian, Maro, Masarova, Lucia, Issa, Ghayas, Wang, Xuemei, Carlos, Bueso-Ramos, Yilmaz, Musa, Kadia, Tapan, Andreeff, Michael, Ravandi, Farhad, Konopleva, Marina, Kantarjian, Hagop M., DiNardo, Courtney D.

“…Preclinically, enasidenib and azacitidine (ENA + AZA) synergistically enhance cell differentiation, and venetoclax (VEN), a small molecule Bcl2 inhibitor (i)…”
Get full text

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia by Pan, Rongqing, Hogdal, Leah J, Benito, Juliana M, Bucci, Donna, Han, Lina, Borthakur, Gautam, Cortes, Jorge, DeAngelo, Daniel J, Debose, Lakeisha, Mu, Hong, Döhner, Hartmut, Gaidzik, Verena I, Galinsky, Ilene, Golfman, Leonard S, Haferlach, Torsten, Harutyunyan, Karine G, Hu, Jianhua, Leverson, Joel D, Marcucci, Guido, Müschen, Markus, Newman, Rachel, Park, Eugene, Ruvolo, Peter P, Ruvolo, Vivian, Ryan, Jeremy, Schindela, Sonja, Zweidler-McKay, Patrick, Stone, Richard M, Kantarjian, Hagop, Andreeff, Michael, Konopleva, Marina, Letai, Anthony G

“…B-cell leukemia/lymphoma 2 (BCL-2) prevents commitment to programmed cell death at the mitochondrion. It remains a challenge to identify those tumors that are…”
Get more information

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia by Alfayez, Mansour, Issa, Ghayas C., Patel, Keyur P., Wang, Feng, Wang, Xuemei, Short, Nicholas J., Cortes, Jorge E., Kadia, Tapan, Ravandi, Farhad, Pierce, Sherry, Assi, Rita, Garcia-Manero, Guillermo, DiNardo, Courtney D., Daver, Naval, Pemmaraju, Naveen, Kantarjian, Hagop, Borthakur, Gautam

“…While germline and somatic mutations in the gene PTPN11 , encoding a phosphatase which regulates the RAS signaling pathway, are well characterized in children…”
Get full text

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience by Kantarjian, Hagop, O'Brien, Susan, Jabbour, Elias, Garcia-Manero, Guillermo, Quintas-Cardama, Alfonso, Shan, Jenny, Rios, Mary Beth, Ravandi, Farhad, Faderl, Stefan, Kadia, Tapan, Borthakur, Gautam, Huang, Xuelin, Champlin, Richard, Talpaz, Moshe, Cortes, Jorge

“…A total of 1569 patients with chronic myeloid leukemia (CML) referred to our institution within 1 month of diagnosis since 1965 were reviewed: 1148 chronic…”
Get full text

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera by QUINTAS-CARDAMA, Alfonso, KANTARJIAN, Hagop, VERSTOVSEK, Srdan, MANSHOURI, Taghi, LUTHRA, Rajyalakshmi, ESTROV, Zeev, PIERCE, Sherry, RICHIE, Mary Ann, BORTHAKUR, Gautam, KONOPLEVA, Marina, CORTES, Jorge

“…We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-alpha-2a) in patients with essential thrombocythemia (ET) and polycythemia vera (PV)…”
Get full text

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies by Borthakur, Gautam, Popplewell, Leslie, Boyiadzis, Michael, Foran, James, Platzbecker, Uwe, Vey, Norbert, Walter, Roland B., Olin, Rebecca, Raza, Azra, Giagounidis, Aristoteles, Al‐Kali, Aref, Jabbour, Elias, Kadia, Tapan, Garcia‐Manero, Guillermo, Bauman, John W., Wu, Yuehui, Liu, Yuan, Schramek, Dan, Cox, Donna S., Wissel, Paul, Kantarjian, Hagop

“…BACKGROUND RAS/RAF/mitogen‐activated protein kinase activation is common in myeloid malignancies. Trametinib, a mitogen‐activated protein kinase kinase 1…”
Get full text